gut.bmj6d
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its ...
gut.bmj7d
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Immune checkpoint inhibitors (ICI) have led to breakthrough improvements in the management of malignancy including hepatocellular (HCC) and biliary tract cancer, improving decades-old standards of ...
gut.bmj21d
Integration of lipidomics with targeted, single cell, and spatial transcriptomics defines an unresolved pro-inflammatory state in colon cancer
Background Over a century ago, Virchow proposed that cancer represents a chronically inflamed, poorly healing wound. Normal wound healing is represented by a transitory phase of inflammation, followed ...
gut.bmj7d
Genetic variation at 11q23.1 confers colorectal cancer risk by dysregulation of colonic tuft cell transcriptional activator POU2AF2
Correspondence to Dr Susan M Farrington, CRUK Edinburgh Centre, Institute of Genetics and Cancer, The University of Edinburgh, Edinburgh, Edinburgh, UK; susan.farrington{at}ed.ac.uk Objective ...
gut.bmj9d
Impairment of spermatogenesis and sperm motility by the high-fat diet-induced dysbiosis of gut microbes
Objective High-fat diet (HFD)-induced metabolic disorders can lead to impaired sperm production. We aim to investigate if HFD-induced gut microbiota dysbiosis can functionally influence ...
gut.bmj4d
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care
Correspondence to Professor Alexander C Ford, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds LS9 7TF, West Yorkshire, UK; alexf12399{at}yahoo.com Objectives Despite ...
gut.bmj8d
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites
Correspondence to Professor Jun Yu, Institute of Digestive Disease, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; ...
gut.bmj10d
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease
Correspondence to Professor Rohit Loomba, Department of Medicine, University of California San Diego, La Jolla CA 92037, USA; roloomba{at}ucsd.edu Objective Emerging data suggest that a 30% relative ...
gut.bmj9d
Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19
2 Institute of Clinical and Molecular Virology & Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nürnberg, Erlangen, Germany Contributors All authors drafted the manuscript and ...
gut.bmj9d
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies
Objective We performed a meta-analysis of observational studies to quantify the magnitude of the association between non-alcoholic fatty liver disease (NAFLD) and risk of extrahepatic cancers. Design ...
gut.bmj4d
Developments and controversies in the management of oesophageal and gastric varices
2 Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic-IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain Correspondence to ...
gut.bmj9d
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
4 Department of Hepatogastroenterology, Hopital Claude Huriez, CHRU Lille, France Correspondence to: Professor J-F Colombel Department of Hepato-Gastroenterology, Hopital Claude Huriez, CHRU de Lille, ...